Question

I am a breastfeeding mother and i want to know if it is safe to use cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)? Is cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) safe for nursing mother and child? Does cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) extracts into breast milk? Does cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) has any long term or short term side effects on infants? Can cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) influence milk supply or can cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) decrease milk supply in lactating mothers?

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) lactation summary

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) is dangerous in breastfeeding
  • DrLact safety Score for cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) .
  • Usage of cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) is in contradiction to breastfeeding hence if it is must to use cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) usage in lactation

Resuming breastfeeding is likely safe when milk platinum levels are not detected (30 days).

Answer by DrLact: About cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) usage in lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II).[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one case, cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) was still detectable in milk 13 days after a dose of 2.9 mg/kg. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2]Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]

Alternate Drugs

Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Mitoxantrone(Dangerous)
Dactinomycin(Dangerous)
Ipilimumab(Unsafe)
Cetuximab(Unsafe)
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Doxorubicin(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Nivolumab(Unsafe)
Cyclophosphamide(Dangerous)
Rituximab(Low Risk)
Vinblastine(Dangerous)
Cisplatin(Unsafe)
Bevacizumab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Busulfan(Dangerous)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Trastuzumab(Unsafe)
Dacarbazine(Dangerous)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Erlotinib(Unsafe)
Letrozole(Dangerous)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.